Literature DB >> 17046152

Pulmonary function in multiple sclerosis without any respiratory complaints.

Ayse Altintas1, Tuncalp Demir, Hande Demirel Ikitimur, Nurhayat Yildirim.   

Abstract

OBJECTIVES: Pulmonary complications in severe multiple sclerosis (MS) are often seen secondary to respiratory muscle dysfunction. The development of respiratory muscle dysfunction and its association with disability during the course of MS is unknown. In our study, we investigated the predictive value of respiratory muscle functions and the change in forced vital capacity (Delta forced vital capacity [FVC]; FVC upright-FVC supine) to detect deterioration of respiratory muscle functions in the early phase of MS. PATIENTS AND METHODS: Twenty-one MS patients with a median age of 34.5+/-9.45 years were enrolled. Fourteen cases were relapsing-remitting, six were secondary progressive, one was primary progressive type. The mean duration of disease was 10.76+/-6.6 years. Seventeen healthy subjects with a median age of 40.7+/-7.6 years were chosen as a control group. Smoking habit was similar in both groups. Pulmonary function tests (PFT), lung volumes, diffusion, respiratory muscle function ( P(Imax) , P(Emax)), mouth occlusion pressure, and indirect sign of respiratory center function (P(0.1)) tests were performed. PFT were repeated in supine and upright positions.
RESULTS: Our results in the MS group and the control group, respectively, were: diffusion (DL(CO): 18.8+/-4.2 vs. 26.4+/-7.3 mL/mmHg/min), P(I(max) (82.1+/-26.3 vs. 109.1+/-23.3 cm H(2)O), P(E(max) (119.2+/-42 vs. 171.8+/-50.2 cm H(2)O), P(0.1) (2.6+/-0.7 vs. 4.2+/-0.7). All parameters were lower in the MS group compared with the control group (p<0.05). In the MS group, FVC values in the upright position were higher than FVC values in the supine position. The difference in FVC values in MS patients between the upright and supine positions (Delta FVC) was also found to be significantly higher than in the control group (Delta FVC 262.3+/-247.6 (MS), 98.8+/-179.1 mL (CONTROL)) (p<0.01).
CONCLUSION: Our results indicate the presence of pulmonary dysfunction in MS even in the absence of any respiratory symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 17046152     DOI: 10.1016/j.clineuro.2006.09.004

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  7 in total

1.  Predictors of positive outcomes following resistive inspiratory muscle training in non-ambulatory persons with advanced multiple sclerosis.

Authors:  Min Hui Huang; Lisa Doyle; Alexander Burnham; Donna K Fry; Keelin Shea
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-05-23

2.  The effect of pulse methylprednisolone plus theophylline treatment on clinical, pulmonary and inflammatory markers in relapses of multiple sclerosis.

Authors:  Pervin Işeri; Ilknur Başyiğit; Ciğdem Ozerdem; Hüseyin Başyiğit; Hüsnü Efendi; Füsun Yıldız
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

3.  Effects of expiratory muscle strength training on maximal respiratory pressure and swallow-related quality of life in individuals with multiple sclerosis.

Authors:  Erin Pearson Silverman; Sarah Miller; Yi Zhang; Bari Hoffman-Ruddy; James Yeager; Janis J Daly
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-05-29

4.  Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity.

Authors:  Joseph Finkelstein; Eunme Cha; Steven M Scharf
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-24

5.  Pulmonary Function and Respiratory Muscle Strength in Patients with Multiple Sclerosis.

Authors:  Elisabeth Westerdahl; Martin Gunnarsson; Anna Wittrin; Ylva Nilsagård
Journal:  Mult Scler Int       Date:  2021-06-14

6.  Lung volume recruitment in multiple sclerosis.

Authors:  Nadim Srour; Carole LeBlanc; Judy King; Douglas A McKim
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

7.  Off-pump coronary surgery in a patient with multiple sclerosis.

Authors:  V Casati; U F Tesler; E Novelli; A D'Angelo; A Romano; E Stelian; M Scandone; F Guerra
Journal:  Heart Lung Vessel       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.